Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun 130021, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun 130021, China.
Biomolecules. 2022 Dec 2;12(12):1802. doi: 10.3390/biom12121802.
Alzheimer's disease (AD) is the most common type of dementia, but its pathogenesis is not fully understood, and effective drugs to treat or reverse the progression of the disease are lacking. Long noncoding RNAs (lncRNAs) are abnormally expressed and deregulated in AD and are closely related to the occurrence and development of AD. In addition, the high tissue specificity and spatiotemporal specificity make lncRNAs particularly attractive as diagnostic biomarkers and specific therapeutic targets. Therefore, an in-depth understanding of the regulatory mechanisms of lncRNAs in AD is essential for developing new treatment strategies. In this review, we discuss the unique regulatory functions of lncRNAs in AD, ranging from Aβ production to clearance, with a focus on their interaction with critical molecules. Additionally, we highlight the advantages and challenges of using lncRNAs as biomarkers for diagnosis or therapeutic targets in AD and present future perspectives in clinical practice.
阿尔茨海默病（AD）是最常见的痴呆类型，但它的发病机制尚未完全阐明，缺乏有效药物来治疗或逆转疾病的进展。长链非编码 RNA（lncRNA）在 AD 中异常表达和失调，与 AD 的发生和发展密切相关。此外，lncRNA 具有高组织特异性和时空特异性，使其作为诊断生物标志物和特定治疗靶点特别有吸引力。因此，深入了解 lncRNA 在 AD 中的调控机制对于开发新的治疗策略至关重要。在这篇综述中，我们讨论了 lncRNA 在 AD 中的独特调控功能，从 Aβ 的产生到清除，重点讨论了它们与关键分子的相互作用。此外，我们还强调了将 lncRNA 用作 AD 诊断生物标志物或治疗靶点的优势和挑战，并提出了未来在临床实践中的展望。
Zotero 插件
